Disposition of guanadrel in subjects with normal and impaired renal function.
The disposition of a single 25 mg oral dose of guanadrel was evaluated in 22 subjects with various degrees of renal function. The terminal elimination half-life was significantly prolonged in subjects with a creatinine clearance (ClCr) less than 30 mL/min/1.73 m2 (19.2 +/- 16.8 h) compared to 3.7 +/- 1.9 h in subjects with a ClCr greater than 80 mL/min/1.73 m2. Apparent total body clearance (Clp/F) was also progressively lower in the patients with decreased renal function and the decline was significantly correlated with ClCr (Clp/F = 0.0294 + 0.0236 Clcr, r = 0.74, P = 0.002). Renal clearance and apparent nonrenal clearance also declined as creatinine clearance decreased, and both were significantly correlated with the observed ClCr. Apparent volume of distribution averaged 11.5 +/- 8.9 L/kg and did not differ in patients with decreased renal function compared to those with normal renal function. Thus, the disposition of guanadrel is significantly altered in the presence of renal insufficiency and dosage adjustments may be necessary, especially in patients with ClCr less than 50 ml/min.
Halstenson
C E
CE
Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota 55415.
Opsahl
J A
JA
Abraham
P A
PA
Schwenk
M H
MH
Andreadis
N A
NA
Antal
E J
EJ
Matzke
G R
GR
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000378:metabolism; D005260:Female; D006146:Guanidines / Q000493:pharmacokinetics* / Q000494:pharmacology; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D011674:Pulse / Q000187:drug effects; D013997:Time Factors
D000959:Antihypertensive Agents; D006146:Guanidines; C004945:guanadrel; D003404:Creatinine